Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac versus naphazoline-antazoline eye drops for prevention of ocular complaints after phacoemulsification cataract surgery
IRCT20200217046523N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of ketorolac, naphazoline and antazoline in cataract (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pain, Nausea and 3 more. Started Aug 2020; status: completed.
02
Drugs
ketorolacnaphazolineantazoline
03
Conditions
cataract
Beyond the preview
Go deeper on IRCT20200217046523N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046523N1.